IBDEI0NB ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,11417,0)
 ;;=V45.81^^64^697^29
 ;;^UTILITY(U,$J,358.3,11417,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11417,1,4,0)
 ;;=4^V45.81
 ;;^UTILITY(U,$J,358.3,11417,1,5,0)
 ;;=5^Hx of CABG
 ;;^UTILITY(U,$J,358.3,11417,2)
 ;;=^97129
 ;;^UTILITY(U,$J,358.3,11418,0)
 ;;=V15.84^^64^697^28
 ;;^UTILITY(U,$J,358.3,11418,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11418,1,4,0)
 ;;=4^V15.84
 ;;^UTILITY(U,$J,358.3,11418,1,5,0)
 ;;=5^Hx of Asbestos Exposure
 ;;^UTILITY(U,$J,358.3,11418,2)
 ;;=^303406
 ;;^UTILITY(U,$J,358.3,11419,0)
 ;;=V15.85^^64^697^47
 ;;^UTILITY(U,$J,358.3,11419,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11419,1,4,0)
 ;;=4^V15.85
 ;;^UTILITY(U,$J,358.3,11419,1,5,0)
 ;;=5^Hx of Potentially Hazardous Body Fluids
 ;;^UTILITY(U,$J,358.3,11419,2)
 ;;=^303407
 ;;^UTILITY(U,$J,358.3,11420,0)
 ;;=V10.72^^64^697^34
 ;;^UTILITY(U,$J,358.3,11420,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11420,1,4,0)
 ;;=4^V10.72
 ;;^UTILITY(U,$J,358.3,11420,1,5,0)
 ;;=5^Hx of Hodgkin's Disease
 ;;^UTILITY(U,$J,358.3,11420,2)
 ;;=^295237
 ;;^UTILITY(U,$J,358.3,11421,0)
 ;;=V15.3^^64^697^35
 ;;^UTILITY(U,$J,358.3,11421,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11421,1,4,0)
 ;;=4^V15.3
 ;;^UTILITY(U,$J,358.3,11421,1,5,0)
 ;;=5^Hx of Irradiation
 ;;^UTILITY(U,$J,358.3,11421,2)
 ;;=^295285
 ;;^UTILITY(U,$J,358.3,11422,0)
 ;;=V10.61^^64^697^37
 ;;^UTILITY(U,$J,358.3,11422,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11422,1,4,0)
 ;;=4^V10.61
 ;;^UTILITY(U,$J,358.3,11422,1,5,0)
 ;;=5^Hx of Lymphoid Leukemia
 ;;^UTILITY(U,$J,358.3,11422,2)
 ;;=Hx of Lymphoid Leukemia^295232
 ;;^UTILITY(U,$J,358.3,11423,0)
 ;;=V12.03^^64^697^39
 ;;^UTILITY(U,$J,358.3,11423,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11423,1,4,0)
 ;;=4^V12.03
 ;;^UTILITY(U,$J,358.3,11423,1,5,0)
 ;;=5^Hx of Malaria
 ;;^UTILITY(U,$J,358.3,11423,2)
 ;;=Hx of Malaria^303395
 ;;^UTILITY(U,$J,358.3,11424,0)
 ;;=V10.82^^64^697^40
 ;;^UTILITY(U,$J,358.3,11424,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11424,1,4,0)
 ;;=4^V10.82
 ;;^UTILITY(U,$J,358.3,11424,1,5,0)
 ;;=5^Hx of Malignant Melanoma
 ;;^UTILITY(U,$J,358.3,11424,2)
 ;;=Hx of Malignant Melanoma^295240
 ;;^UTILITY(U,$J,358.3,11425,0)
 ;;=V10.62^^64^697^43
 ;;^UTILITY(U,$J,358.3,11425,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11425,1,4,0)
 ;;=4^V10.62
 ;;^UTILITY(U,$J,358.3,11425,1,5,0)
 ;;=5^Hx of Myeloid Leukemia
 ;;^UTILITY(U,$J,358.3,11425,2)
 ;;=Hx of Myeloid Leukemia^295233
 ;;^UTILITY(U,$J,358.3,11426,0)
 ;;=V10.63^^64^697^41
 ;;^UTILITY(U,$J,358.3,11426,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11426,1,4,0)
 ;;=4^V10.63
 ;;^UTILITY(U,$J,358.3,11426,1,5,0)
 ;;=5^Hx of Monocytic Leukemia
 ;;^UTILITY(U,$J,358.3,11426,2)
 ;;=Hx of Monocytic Leukemia^295234
 ;;^UTILITY(U,$J,358.3,11427,0)
 ;;=V11.2^^64^697^32
 ;;^UTILITY(U,$J,358.3,11427,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11427,1,4,0)
 ;;=4^V11.2
 ;;^UTILITY(U,$J,358.3,11427,1,5,0)
 ;;=5^Hx of Dysthymia
 ;;^UTILITY(U,$J,358.3,11427,2)
 ;;=Hx of Dysthymia^295251
 ;;^UTILITY(U,$J,358.3,11428,0)
 ;;=V15.81^^64^697^60
 ;;^UTILITY(U,$J,358.3,11428,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11428,1,4,0)
 ;;=4^V15.81
 ;;^UTILITY(U,$J,358.3,11428,1,5,0)
 ;;=5^Noncompliance With Medical Treatment
 ;;^UTILITY(U,$J,358.3,11428,2)
 ;;=^295290
 ;;^UTILITY(U,$J,358.3,11429,0)
 ;;=V10.43^^64^697^44
 ;;^UTILITY(U,$J,358.3,11429,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11429,1,4,0)
 ;;=4^V10.43
 ;;^UTILITY(U,$J,358.3,11429,1,5,0)
 ;;=5^Hx of Ovarian CA
 ;;^UTILITY(U,$J,358.3,11429,2)
 ;;=Hx of Ovarian CA^295221
 ;;^UTILITY(U,$J,358.3,11430,0)
 ;;=V12.71^^64^697^45
